S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
NASDAQ:RGEN

Repligen - RGEN Stock Forecast, Price & News

$192.91
-2.27 (-1.16%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$189.19
$196.60
50-Day Range
$154.26
$195.18
52-Week Range
$137.21
$262.26
Volume
350,811 shs
Average Volume
544,859 shs
Market Capitalization
$10.71 billion
P/E Ratio
66.52
Dividend Yield
N/A
Price Target
$224.14

Repligen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
16.2% Upside
$224.14 Price Target
Short Interest
Bearish
7.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
0.80mentions of Repligen in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$5 M Sold Last Quarter
Proj. Earnings Growth
-7.26%
From $3.17 to $2.94 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

518th out of 1,025 stocks

Biological Products, Except Diagnostic Industry

84th out of 168 stocks

RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Repligen (NASDAQ:RGEN) Sees Unusually-High Trading Volume
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Why Shares of Repligen Rose This Week
HZNP vs. RGEN: Which Stock Is the Better Value Option?
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
BIIB or RGEN: Which Is the Better Value Stock Right Now?
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
Repligen to Report Third Quarter 2022 Financial Results
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Company Calendar

Last Earnings
10/28/2021
Today
2/05/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$224.14
High Stock Price Forecast
$275.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+16.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$128.29 million
Pretax Margin
25.08%

Debt

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$4.07 per share
Book Value
$31.65 per share

Miscellaneous

Free Float
54,913,000
Market Cap
$10.71 billion
Optionable
Optionable
Beta
1.08

Social Links


Key Executives

  • Tony J. Hunt
    President, Chief Executive Officer & Director
  • James R. BylundJames R. Bylund
    Chief Operating Officer
  • Jon K. SnodgresJon K. Snodgres
    Chief Financial Officer
  • Ralf KuriyelRalf Kuriyel
    Senior Vice President-Research & Development
  • Christine GebskiChristine Gebski
    Senior VP-Filtration & Chromatography













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2023?

7 equities research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price forecasts range from $180.00 to $275.00. On average, they anticipate the company's stock price to reach $224.14 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2023?

Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has increased by 13.9% and is now trading at $192.91.
View the best growth stocks for 2023 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. The biotechnology company earned $178.22 million during the quarter, compared to analyst estimates of $163.97 million. Repligen had a net margin of 20.76% and a trailing twelve-month return on equity of 10.98%. The company's revenue for the quarter was up 89.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.40 earnings per share.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.15-$3.20 for the period, compared to the consensus estimate of $3.20. The company issued revenue guidance of $795.00 million-$805.00 million, compared to the consensus revenue estimate of $803.99 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by many different retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (1.23%), Stephens Investment Management Group LLC (0.98%), Pendal Group Ltd (0.84%), New York State Common Retirement Fund (0.78%), Allspring Global Investments Holdings LLC (0.54%) and Sumitomo Mitsui Trust Holdings Inc. (0.24%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $192.91.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $10.71 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.90 on an earnings per share basis.

How many employees does Repligen have?

The company employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 2/5/2023 by MarketBeat.com Staff